Andira research scientist Dr. Claudia Dietrich, presented “Synergy Unleashed: Silver and Cannabinoids for Superior Antimicrobial Action in Skin Wound Healing”, a talk about Andira’s Marix3™ Antimicrobial technology, to the top plastic surgeons in the Vancouver area, at the University of British Columbia (UBC) Plastic Surgery Research Day, held May 10, 2024 at the Pan Pacific Hotel in Vancouver winning BEST Oral Presentation. Congratulations to Dr. Dietrich!
Dr. Dietrich’s research has led to significantly increasing the efficacy of Marix3™ Antimicrobial technology resulting in faster onset, higher kill rates, and reduced resistance potential. Andira CEO, Dana Lambert, PhD, describes Dr. Dietrich’s work as, “nothing short of extraordinary.”
Matrix3™ Antimicrobial replaces conventional silver, a globally recognized infection control standard across the healthcare and consumer goods industries. It combines cannabinoids with silver to amplify silver’s effectiveness by 800%, promising to greatly improve patient outcomes for treating and preventing infection, both inside and outside of healthcare settings. Matrix3TM Antimicrobial is a paradigm shift for infection control, raising the global standard of antimicrobial protection in healthcare settings and consumer goods.
Plastic surgeons were impressed with Andira’s breakthrough innovation; many remarked they are keen to put Matrix3TM Shield, a Matrix3TM containing advanced wound dressing, to work upon product approval, which is expected in 2026. Andira is currently exploring partnership opportunities for Matrix3TM Antimicrobial in product categories outside of wound care.
###
About Andira Pharmaceuticals: Andira is a private health technology company that boosts the efficacy of approved medical treatments for infection control and oncology by leveraging a proprietary synergistic amplification platform.
Learn more at www.andira.ca
